Get the Stockscreener App
0.6599
1.18%
-0.0079
Bioaffinity Technologies Inc stock is traded at $0.6599, with a volume of 128.76K.
It is down -1.18% in the last 24 hours and down -22.41% over the past month.
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
See More
Previous Close:
$0.6678
Open:
$0.6678
24h Volume:
128.76K
Relative Volume:
0.32
Market Cap:
$4.15M
Revenue:
$5.66M
Net Income/Loss:
$-15.88M
P/E Ratio:
-0.0583
EPS:
-11.3134
Net Cash Flow:
$-10.93M
1W Performance:
-6.22%
1M Performance:
-22.41%
6M Performance:
-51.12%
1Y Performance:
-93.66%
1-Day Range:
$0.6481
$0.7006
1-Week Range:
$0.6421
$0.7234
52-Week Range:
$0.6121
$13.50
Bioaffinity Technologies Inc Stock (BIAF) Company Profile
Name
Bioaffinity Technologies Inc
Sector
Industry
Phone
210-698-5334
Address
3300 NACOGDOCHES ROAD, SAN ANTONIO
Compare BIAF vs TMO, DHR, IDXX, A, NTRA
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIAF
Bioaffinity Technologies Inc
|
0.6599 | 4.15M | 5.66M | -15.88M | -10.93M | -11.31 |
TMO
Thermo Fisher Scientific Inc
|
568.26 | 211.18B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
191.50 | 134.62B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
544.32 | 42.94B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
138.57 | 39.14B | 7.23B | 1.41B | 1.09B | 4.979 |
NTRA
Natera Inc
|
261.99 | 37.52B | 2.50B | -226.32M | 71.51M | -1.6412 |
Bioaffinity Technologies Inc Stock (BIAF) Latest News
Top QumulusAI (QMLS) Competitors 2026 - MarketBeat
bioAffinity Technologies, Inc. (BIAF) stock price, news, quote and history - Yahoo Finance UK
bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity's Diagnostics for Asthma and COPD | Newswise - Newswise
TradingKey - TradingKey
BIAF|bioAffinity Technologies Inc|Price:0.663|Chg%:-0.005 - TradingKey
BIAF vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now? - Zacks Investment Research
What's Driving bioAffinity Technologies' Recent Surge - Kavout | AI
BioAffinity Technologies and Pictor, Inc. Partner to Develop and Commercialize bioAffinity's Diagnostics for Asthma and COPD - marketscreener.com
bioAffinity Technologies, Inc. (BIAF) Stock Price, News, Quote & History - Yahoo! Finance Canada
bioAffinity and Pictor partner on diagnostics for asthma and COPD - Yahoo Finance
bioAffinity Technologies Inc (BIAF) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
BioAffinity Technologies Inc (BIAF) Fundamental & Financial Data - Stocktwits
bioAffinity Technologies and Pictor Partner to Develop High-Throughput, Cost-Effective Diagnostics for Asthma and COPD – Minichart - Minichart
bioAffinity and Pictor partner on lung inflammation diagnostics - TipRanks
bioAffinity partners with Pictor on asthma, COPD tests - Investing.com
bioAffinity Technologies partners with Pictor to develop high-throughput asthma and COPD diagnostics - TradingView
bioAffinity partners with Pictor on asthma, COPD tests By Investing.com - Investing.com Canada
, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD - Business Wire
BIAF|bioAffinity Technologies Inc|Price:0.670|Chg%:+0.002 - TradingKey
Transcript : BioAffinity Technologies, Inc.Special Call - marketscreener.com
Certain Options of bioAffinity Technologies, Inc. are subject to a Lock-Up Agreement Ending on 19-JUL-2026. - marketscreener.com
Certain Warrants of bioAffinity Technologies, Inc. are subject to a Lock-Up Agreement Ending on 19-JUL-2026. - marketscreener.com
Certain Common Stock of bioAffinity Technologies, Inc. are subject to a Lock-Up Agreement Ending on 19-JUL-2026. - marketscreener.com
BIAF Stock Gains As CyPath Sales Surge 146% In Q1 - Stocktwits
bioAffinity Technologies Initiates New Study for Expanding CyPath Lung Tech - Medical Product Outsourcing
bioAffinity Technologies Inc Warrant 2022- on bioAffinity Financial Disclosures & SEC Filings - TradingView
BIAF stock plunges 77% in 3 months: Should you still hold or sell? - MSN
BIAF Stock Plunges 77% in 3 Months: Should You Still Hold or Sell? - The Globe and Mail
Multidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies’ Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy Webinar - AOL.com
WallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million Offering - AOL.com
bioAffinity reports 200% jump in lung test sales year-over-year By Investing.com - Investing.com South Africa
bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues - BioSpace
bioAffinity Technologies’ CyPath Lung Test Sees Rapid Growth - TipRanks
bioAffinity Technologies Sets New Record as CyPath® Lung Sales Double with Over 200% Year-Over-Year Growth in Q2 2026 1 – Minichart - Minichart
bioAffinity reports 200% jump in lung test sales year-over-year - Investing.com
bioAffinity Technologies Q2 CyPath® Lung Sales More Than Double Year‑Over‑Year - TradingView
CyPath Lung demand surges as bioAffinity (BIAF) Q2 2026 test volume more than triples - Stock Titan
bioAffinity Technologies (BIAF) Holds Near Support as Trading Volume Remains ElevatedNaked POC - dars.gov.et
bioAffinity Technologies Sees Record CyPath® Lung Test Sales, Expands Veteran Screening with Philips Partnership - Minichart
bioAffinity Highlights Surge in CyPath Lung Test Adoption - TipRanks
bioAffinity Technologies reports accelerated CyPath Lung sales, Philips partnership to boost veteran screening - TradingView
CyPath Lung sales surge as bioAffinity (NASDAQ: BIAF) expands pipeline - Stock Titan
bioAffinity Technologies Company Profile & Introduction - Moomoo
BIAF Q3 2025 Earnings: EPS Misses Estimates as Company Continues R&D FocusForward EPS Estimate - DonanımHaber
bioAffinity Technologies Inc (BIAF) Valuation: PE, PB & Fair Value Analysis - TradingKey
bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells - BioSpace
bioAffinity Technologies reports skin cancer siRNA preclinical results - grafa.com
bioAffinity to present skin cancer treatment research - Investing.com
bioAffinity to present skin cancer treatment research By Investing.com - Investing.com South Africa
BIOAFFINITY TECHNOLOGIES INC (BIAF) Stock Chart - ChartMill
BioAffinity Technologies Closes $3.2 Million Public Offering - Moomoo
Bioaffinity Technologies Inc Stock (BIAF) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.02%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):